Edwards Lifesciences (NYSE:EW) benefits from a rating upgrade by Sanford C. Bernstein

2 min read | October 30, 2024 04:57 AM PDT | By Team Kalkine Media

Google News:

Edwards Lifesciences (NYSE:EW) benefits from a rating upgrade by Sanford C. Bernstein — Image source: Shutterstock

Recent News

Why Moderna Is Capturing Market Attention Again?

Eli Lilly Coverage Buzz Keeps Healthcare Market Attention High

Sandisk Gains Attention As an AI-Driven Growth Stock

Why Micron Technology Is Benefiting From the AI Growth Wave?

Make Kalkine Media
My Trusted Source

Highlights

Edwards Lifesciences received an upgrade from "strong sell" to "hold" from Sanford C. Bernstein amid a challenging market environment.

The company reported earnings that met analyst estimates but experienced a decline in revenue compared to expectations.

Institutional investors remain active, with significant holdings and recent changes in positions reflecting ongoing interest in the company.

Edwards Lifesciences (NYSE:EW) has been upgraded by Sanford C. Bernstein, moving from a "strong sell" rating to a "hold" rating as analysts assess the company's performance amidst fluctuating market conditions. This adjustment reflects the ongoing challenges faced by the company, which specializes in products and technologies for structural heart disease and critical care monitoring.

In its latest earnings report, Edwards Lifesciences announced adjusted earnings per share of $0.67, aligning with analysts' expectations. However, the company faced a revenue decline, reporting $1.35 billion for the quarter, falling short of the anticipated $1.57 billion. Despite these challenges, the company’s revenue demonstrated an 8.9% year-over-year increase. Notably, the net margin was reported at 24.55%, and return on equity stood at 22.35%.

The market reaction to these developments has been mixed, with analysts from other firms also weighing in. UBS Group lowered its price objective for the stock, while Daiwa Capital Markets upgraded its rating to "outperform." The consensus rating for Edwards Lifesciences currently stands at "Hold," with a target price of approximately $75.67.

The company’s stock performance reflects a range of investor sentiments, with shares opening at $69.37. Key financial metrics indicate a market capitalization of $41.80 billion and a price-to-earnings ratio of 29.90. The stock has experienced significant volatility, with a fifty-two week low of $58.93 and a high of $96.12.

Institutional investors play a crucial role in the company's equity structure, with hedge funds and other institutional entities holding 79.46% of the stock. Recent changes in holdings by major players, such as Vanguard Group and Bank of New York Mellon, underscore continued interest and potential confidence in the company's long-term prospects.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.